Insmed's HS trial just face-planted

Oof, that’s not the kind of readout you want

Insmed dropped fresh data from its Phase 2b CEDAR trial, and the headline basically writes itself: brensocatib didn’t do enough for hidradenitis suppurativa, so the company is pulling the plug on the HS program.

The study tested 214 adults with moderate to severe HS in a randomized, double-blind, placebo-controlled setup. That sounds fancy, but the scoreboard is what matters — and the placebo group actually did better than the drug arms on the key Week 16 readout.

The placebo got the last laugh

Here’s the awkward part for investors:

• Placebo: 57.1% reduction in abscess and inflammatory nodule count
• Brensocatib 10 mg: 45.5% reduction
• Brensocatib 40 mg: 40.3% reduction

So yeah, the experimental drug didn’t just miss the primary endpoint — it missed the vibe check too. The stock took an after-hours hit of about 2%, which is the market’s way of saying, “thanks, but no thanks.”

Safety wasn’t the problem

To be fair, this wasn’t a safety disaster. Insmed said brensocatib was well tolerated and there were no new safety signals, even at the highest dose. But in biotech, tolerable and effective are two very different dinner guests. One shows up on time; the other actually helps pay for the meal.

Big picture

For investors, the key takeaway is simple: Insmed is losing a potential growth leg in HS, and that usually means the story shifts back to the company’s remaining pipeline and core execution. In biotech, a failed trial doesn’t just kill a program — it can also quietly erase a chunk of the future investors were pricing in.